All lobbying filings

TODD STRATEGY GROUP

Lobbying for PFIZER INC. · Biopharmaceutical company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Mar 17, 2026

Official filing document

Bills named in this filing 3

S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
HR 2214
DRUG Act

Lobbying activity 3

Pharmacy

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.

Tariff (miscellaneous tariff bills)

Issues related to tariff and trade policy. International Supply Chain.

Trade (domestic/foreign)

Issues related to tariff and trade policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.